Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England,... by Bedston, S, Almaghrabi, F, Patterson, L, Agrawal, U, Woolford, L, Anand, SN, Joy, M, Crawford, A, Goudie, R, Byford, R, Abbasizanjani, H, Smith, D, Laidlaw, L, Akbari, A, Sullivan, C, Bradley, DT, Lyons, RA, de Lusignan, S, Hobbs, FDR, Robertson, C, Sheikh, SA, Shi, T

“…<strong>Background<br></strong> UK COVID-19 vaccination policy has evolved to offering COVID-19 booster doses to individuals at increased risk of severe Illness from COVID-19. …”

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in Englan... by Agrawal, U, Bedston, S, McCowan, C, Oke, J, Patterson, L, Robertson, C, Akbari, A, Azcoaga-Lorenzo, A, Bradley, DT, Fagbamigbe, AF, Grange, Z, Hall, ECR, Joy, M, Katikireddi, SV, Kerr, S, Ritchie, L, Murphy, S, Owen, RK, Rudan, I, Shah, SA, Simpson, CR, Torabi, F, Tsang, RSM, de Lusignan, S, Lyons, RA, O'Reilly, D, Sheikh, A

“…<p><strong>Background</strong></p> Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. …”

Disparities in COVID-19 mortality amongst the immunosuppressed: a systematic review and meta-analysis for enhanced disease surveillance by Leston, M, Elson, W, Ordóñez-Mena, JM, Kar, D, Whitaker, H, Joy, M, Roberts, N, Hobbs, FDR, de Lusignan, S

“…This novel means of subdivision has prospective benefit for targeting patient triage, shielding and vaccination policies during periods of high disease transmission.…”

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study by Agrawal, U, Katikireddi, SV, McCowan, C, Mulholland, RH, Azcoaga-Lorenzo, A, Amele, S, Fagbamigbe, AF, Vasileiou, E, Grange, Z, Shi, T, Kerr, S, Moore, E, Murray, JLK, Shah, SA, Ritchie, L, O'Reilly, D, Stock, SJ, Beggs, J, Chuter, A, Torabi, F, Akbari, A, Bedston, S, McMenamin, J, Wood, R, Tang, RSM, de Lusignan, S, Hobbs, FDR, Woolhouse, M, Simpson, CR, Robertson, C, Sheikh, A

“…Sociodemographic and clinical features known to increase the risk of severe disease in unvaccinated populations were also associated with severe outcomes in people receiving their first dose of vaccine and could help inform case management and future vaccine policy formulation. …”

First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotl... by Kerr, S, Joy, M, Torabi, F, Bedston, S, Akbari, A, Agrawal, U, Beggs, J, Bradley, D, Chuter, A, Docherty, AB, Ford, D, Hobbs, R, Katikireddi, SV, Lowthian, E, de Lusignan, S, Lyons, R, Marple, J, McCowan, C, McGagh, D, McMenamin, J, Moore, E, Murray, J-LK, Owen, RK, Pan, J, Ritchie, L, Shah, SA, Shi, T, Stock, S, Tsang, RSM, Vasileiou, E, Woolhouse, M, Simpson, CR, Robertson, C, Sheikh, A

“…This evidence may be useful in risk–benefit analyses of vaccine policies and in providing quantification of risks associated with vaccination to the general public.…”